Latest Articles
Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market - openpr.com
Segment Analysis and Major Growth Areas in the Endometrial Cancer Treatment Market openpr.com
Published: Aug. 3, 2026, 10:50 a.m.
Lotus Endometriosis Institute Expands Advanced Evaluations As Demand Grows - markets.businessinsider.com
Lotus Endometriosis Institute Expands Advanced Evaluations As Demand Grows markets.businessinsider.com
Published: Aug. 3, 2026, 7:47 a.m.
Endometrial Cancer Market Expected to Witness Significant - openPR.com
Endometrial Cancer Market Expected to Witness Significant openPR.com
Published: Aug. 2, 2026, 5:51 p.m.
Lotus Endometriosis Institute Announces Post-Op Recovery Plans For Endo Patients - StreetInsider
Lotus Endometriosis Institute Announces Post-Op Recovery Plans For Endo Patients StreetInsider
Published: Aug. 2, 2026, 8:46 a.m.
Living with endometriosis? Doctor explains why knowing the signs of ovarian cancer could make all the dif - The Times of India
Living with endometriosis? Doctor explains why knowing the signs of ovarian cancer could make all the dif The Times of India
Published: Aug. 2, 2026, 6:30 a.m.
Lotus Endometriosis Institute Announces Post-Op Recovery Plans For Endo Patients - FinancialContent
Lotus Endometriosis Institute Announces Post-Op Recovery Plans For Endo Patients FinancialContent
Published: Aug. 1, 2026, 11:55 p.m.
Alexander Sørloth 2026 • Magic Skills & Goals & Control • Atlético Madrid ᴴᴰ Endometriosis (7LCBIOHCbC) - Mshale
Alexander Sørloth 2026 • Magic Skills & Goals & Control • Atlético Madrid ᴴᴰ Endometriosis (7LCBIOHCbC) Mshale
Published: Aug. 1, 2026, 4:17 p.m.
FRESH TAKE: Endometriosis – when women are neglected and not believed - Donegal News
FRESH TAKE: Endometriosis – when women are neglected and not believed Donegal News
Published: Aug. 1, 2026, 10:52 a.m.
Karyopharm (KPTI) Shares Collapse 65% After Xpovio Fails Endometrial Cancer Trial Again - londoninsider.co.uk
Karyopharm (KPTI) Shares Collapse 65% After Xpovio Fails Endometrial Cancer Trial Again londoninsider.co.uk
Published: Aug. 1, 2026, 8:33 a.m.
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial Vanguard
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial The Clinical Trial Vanguard
Published: Aug. 1, 2026, 6:33 a.m.
Link copied to clipboard!